No CrossRef data available.
Article contents
Pharmacological treatment strategies in mood, panic and obsessive compulsive disorders
Published online by Cambridge University Press: 18 September 2015
Summary
Since the introduction of the monoamine oxydase inhibitors and the first tricyclic antidepressant (TCA) imipramine in the late fifties, the treatment of depressive disorders has been changed dramatically. Althought a great variety of antidepressants such as TCA's, selective serotoninte-re-uptake inhibitors (SSRI's) mianserin, trazodone, mirtazapine, moclobemide and venlafaxine has become available, the exact mode of action is not revealed as yet, and classification should be done according to the interference of antidepressants with central monoaminergic processes.
As to the potential of causing interactions, special attention has to be given to the SSRI's because of their interference with the CYP450 isozyme system. Therapeutic monotoring is recommended for the TCA's. The choiseforan antidepressant should be based on various factors like symptomatology and severity of the depression, potential interactions and somatic and/or psychiatric comorbidity.
Extensive clinical research has demonstrated that TCA's are the most effective for major depression with melancholia (vital depression) and depressive disorders in the elderly.
Keywords
- Type
- Research Article
- Information
- Copyright
- Copyright © Cambridge University Press 1996
References
Literatuur
1.Kuhn, R. The treatment of depressive states with G-22355 (Imipramine hydrocloride). Am J Psychiat 1958; 115: 459–64.CrossRefGoogle Scholar
5.Praag, HM van. 5-HT-related, anxiety- and/or aggression-driven depression. Int clin Psychopharmacol 1994; 9: S5–S6.CrossRefGoogle ScholarPubMed
10.Greist, JH, Jefferson, JW, Kobak, KA, Katzelnick, DJ, Serlin, RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive compulsive disorder. A meta-analysis. Arch gen Psychiat 1995; 52: 53–60.CrossRefGoogle ScholarPubMed
12.Verhoeven, WMA. De plaats van het geneesmiddel en andere biologische benaderingen binnen de psychiatric Pharmac Weekbl 1994; 20: 506–10.Google Scholar
15.Roose, SP, Glassman, AH, Attia, E, Woodring, S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiat 1994; 151: 1735–9.Google ScholarPubMed
16.Vestergaard, P, Gram, LF, Kragh-Sorensen, P, Bech, P, Reisby, N, Bolwig, TG. Therapeutic potentials of recently introduced antidepressants. Danish University Antidepressant Group. Psychopharmacol Ser 1993; 10: 190–8.Google ScholarPubMed
19.Garvey, M, DeRubeis, RJ, Hollon, SD, Evans, MD, Tuason, VB. Response of depression to very high plasma levels of Imipramine plus desipramine. Biol Psychiat 1991; 30: 57–62.CrossRefGoogle ScholarPubMed
23.Anderson, IM, Tomenson, BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238–49.CrossRefGoogle ScholarPubMed
24.Song, F, Freemantle, N, Shelton, TA, et al.Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br med J 1993; 306: 683–7.CrossRefGoogle ScholarPubMed
25.Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986; 90: 131–8.Google Scholar
26.Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J affect Disord 1990; 18: 289–99.Google Scholar
30.Fux, M, Taub, M, Zohar, J. Emergence of depressive symptoms during treatment for panic disorders with specific 5-hydroxy-tryptophan reuptake inibitors. Acta psychiatr scand 1993; 88: 235–7.CrossRefGoogle Scholar
33.Nolen, WA, Hoencamp, E, Bouvy, PF, Haffmans, PMJ. Reversible monoamine oxidase-A inhibitors in resistant major depression. Clin Neuropharmacol 1993; 16: S69–S76.Google ScholarPubMed
41.Danish University Antidepressant Group. Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled milticenter study. J affect Disord 1993; 28: 105–16.CrossRefGoogle Scholar
51.Greden, JF. Antidepressant maintenance medications: when to discontinue and how to stop. J clin Psychiat 1993:54 (suppl):S39–S45.Google ScholarPubMed
52.Preskorn, SH. Antidepressant drug selection: criteria and options. J clin Psychiat 1994; 55: S6–24.Google ScholarPubMed
54.Kupfer, DJ, Frank, E, Perel, JM, et al.Five-year outcome for maintenance therapies in recurrent depression. Arch gen Psychiat 1992; 49: 769–73.CrossRefGoogle ScholarPubMed
61.NIMH/NIH Consensus Development Panel. Mood disorders: pharmacologic prevention of recurrences (NUMH/NIH Consensus Development Conference Statement). Am J Psychiat 1985; 142: 469–76.CrossRefGoogle Scholar
62.WHO Mental Health Collaborating Centers. Pharmacotherapy of depressive disorders: a consensus statement. J affect Disord 1989; 17: 197–8.CrossRefGoogle Scholar
66.Frank, E, Kupfer, DJ, Perel, JM, et al.Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J affect Disord 1993; 27: 139–45.CrossRefGoogle ScholarPubMed
70.Dilsaver, SC, Greden, JF. Antidepressant withdrawal phenomena. Biol Psychiat 1984; 19: 237–56.Google ScholarPubMed
75.Preskorn, SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J clin Psychiat 1993; 54: S14–S34.Google ScholarPubMed
77.Pato, MT, Murphy, DL, DeVane, CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after discontinuation. J clin Psychopharmacol 1991; 11: 224–5.CrossRefGoogle ScholarPubMed
102.Centraal Begeleidingsorgaan voor de Intercollegiale Toetsing. Depressie bij volwassenen. CBO, 1994.Google Scholar